Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lumateperone deuterated - Intra-Cellular Therapies

Drug Profile

Lumateperone deuterated - Intra-Cellular Therapies

Alternative Names: ITI 1284; ITI-1284 ODT-SL

Latest Information Update: 17 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer Intra-Cellular Therapies
  • Class Antidementias; Antidepressants; Antipsychotics; Behavioural disorder therapies; Fluorobenzenes; Organic deuterium compounds; Piperidines; Pyrroles; Quinoxalines; Sleep disorder therapies; Small molecules; Tosyl compounds
  • Mechanism of Action Dopamine D2 receptor modulators; Glutamate modulators; Serotonin 2A receptor antagonists; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Agitation; Generalised anxiety disorder; Psychotic disorders
  • No development reported Behavioural disorders; Dementia; Depressive disorders

Most Recent Events

  • 11 Apr 2024 Intra-Cellular Therapies initiates a phase-I trial (In volunteers) in USA in March 2024 (Sublingual, Tablet) (NCT06299410)
  • 11 Mar 2024 Intra-Cellular Therapies plans a phase-I trial (In volunteers) in USA in March 2024 (Sublingual, Tablet) (NCT06299410)
  • 28 Jan 2024 No recent reports of development identified for phase-I development in Behavioural-disorders(In the elderly, In volunteers, In adults) in USA (Sublingual, Tablet)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top